Suchergebnisse - "Bhagani, Sanjay"

PubPharm (7)

1

Tixagevimab-cilgavimab for treatment of patients hospitalised with COVID-19 : a randomised, double-blind, phase 3 trial

enthalten in: The Lancet. Respiratory medicine | 2022

von ACTIV-3–Therapeutics for Inpatients with COVID-19 (TICO) Study Group | Ginde, A. | Paredes, R. | +98

CommentIn: Lancet Respir Med. 2022 Oct;10(10):928-930. - PMID 35817073

2

Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients

enthalten in: The New England journal of medicine | 2022

von Jayk Bernal, A. | Gomes da Silva, M. | Musungaie, D. | +120

CommentIn: N Engl J Med. 2022 Feb 10;386(6):592-593. - PMID 34914869

3

Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC) : a double-blind, placebo-controlled, phase 3, randomised trial

enthalten in: Lancet (London, England) | 2022

von ITAC (INSIGHT 013) Study Group | Polizzotto, M. | Nordwall, J. | +86

4

Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia

enthalten in: The New England journal of medicine | 2021

von Rosas, I. | Bräu, N. | Waters, M. | +20

CommentIn: N Engl J Med. 2021 Apr 22;384(16):1564-1565. - PMID 33631064

5

Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19 : A Randomized Clinical Trial

enthalten in: JAMA | 2020

von Spinner, C. | Gottlieb, R. | Criner, G. | +28

CommentIn: JAMA. 2020 Sep 15;324(11):1041-1042. - PMID 32821934

6

Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2) : a multicentre, open-label, non-randomised, phase 3 study

enthalten in: Lancet (London, England) | 2015

von Molina, J. | Orkin, C. | Iser, D. | +52

CommentIn: Lancet. 2015 Mar 21;385(9973):1052-4. - PMID 25659286

7

Faldaprevir and pegylated interferon α-2a/ribavirin in individuals co-infected with hepatitis C virus genotype-1 and HIV

enthalten in: AIDS (London, England) | 2015

von Dieterich, D. | Nelson, M. | Soriano, V. | +13

1
[1]